Effects of antiproteinuric intervention on elevated Connective Tissue Growth Factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 8, 2011, Pages 1845-1850

  Slagman, Maartje C J ^a   Nguyen, Tri Q ^b   Waanders, Femke ^a   Vogt, Liffert ^a   Hemmelder, Marc H ^c   Laverman, Gozewijn D ^a   Goldschmeding, Roel ^b   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; MONOTHERAPY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SODIUM INTAKE; SODIUM RESTRICTION; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; CONNECTIVE TISSUE GROWTH FACTOR; CROSS-OVER STUDIES; DIET, SODIUM-RESTRICTED; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; KIDNEY DISEASES; LOSARTAN; MALE; MIDDLE AGED; NETHERLANDS; PROTEINURIA; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 80051556515     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08190910     Document Type: Article

References (46)

1. Leask A, Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827, 2004
2. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K: Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: A potential target for preventing renal fibrosis. Am J Kidney Dis 38: S134-S138, 2001
3. Qi W, Chen X, Poronnik P, Pollock CA: Transforming growth factor-beta/connective tissue growth factor axis in the kidney. Int J Biochem Cell Biol 40: 9-13, 2008
4. Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K, Yoshioka T, Saito Y, Ogawa Y, Kuwabara T, Sugawara A, Nakao K: Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73: 446-455, 2008
5. Wang S, Denichilo M, Brubaker C, Hirschberg R: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60: 96-105, 2001
6. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Hoppener JW, Goldschmeding R: Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/ CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 290: F1344-F1354, 2006
7. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53: 853-861, 1998
8. Kobayashi T, Okada H, Inoue T, Kanno Y, Suzuki H: Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrol Dial Transplant 21: 548-549, 2006
9. Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van Nieuwenhoven FA: Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29: 83-88, 2006
10. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G: Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26: 2632-2636, 2003
11. Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW: Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 93: 1893-1900, 2008
12. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R: Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31: 1177-1182, 2008
13. Sonnylal S, Shi-Wen X, Leoni P, Naff K, Van Pelt CS, Nakamura H, Leask A, Abraham D, Bou-Gharios G, de Crombrugghe B: Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum 62: 1523-1532, 2010
14. Guo-Qiu W, Nai-Feng L, Xiao-Bo V, Linxian L, Chen Z, Lixia G, Zhao L: The level of connective tissue growth factor in sera of patients with hepatitis B virus strongly correlates with stage of hepatic fibrosis. Viral Immunol 23: 71-78, 2010
15. Nguyen TQ, Goldschmeding R: Bone morphogenetic protein-7 and connective tissue growth factor: Novel targets for treatment of renal fibrosis? Pharm Res 25: 2416-2426, 2008
16. Deelman L, Sharma K: Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens 18: 85-90, 2009
17. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001
18. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998
19. Amann K, Tyralla K: Cardiovascular changes in chronic renal failure: Pathogenesis and therapy. Clin Nephrol 58[Suppl 1]: S62-S72, 2002
20. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G: Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19: 999-1007, 2008
21. Yang DH, Kim HS, Wilson EM, Rosenfeld RG, Oh Y: Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. J Clin Endocrinol Metab 83: 2593-2596, 1998
22. Gerritsen KG, Peters HP, Nguyen TQ, Koeners MP, Wetzels JF, Joles JA, Christensen EI, Verroust PJ, Li D, Oliver N, Xu L, Kok RJ, Goldschmeding R: Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. Am J Physiol Renal Physiol 298: F1457-F1464, 2010
23. D'Amico G, Bazzi C: Pathophysiology of proteinuria. Kidney Int 63: 809-825, 2003
24. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G: Effect of reninangiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: A post hoc analysis of a randomized controlled trial. Am J Kidney Dis 53: 16-25, 2009
25. Kramer AB, van der Meulen EF, Hamming I, van Goor H, Navis G: Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 71: 417-424, 2007
26. Iwanciw D, Rehm M, Porst M, Goppelt-Struebe M: Induction of connective tissue growth factor by angiotensin II: Integration of signaling pathways. Arterioscler Thromb Vasc Biol 23: 1782-1787, 2003
27. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M: Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108: 1499-1505, 2003
28. Groholm T, Finckenberg P, Palojoki E, Saraste A, Backlund T, Eriksson A, Laine M, Mervaala E, Tikkanen I: Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. Hypertens Res 27: 609-618, 2004
29. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI: Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98: 2621-2628, 1998
30. Ying WZ, Sanders PW: Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 274: F635-F641, 1998
31. Nonaka Takahashi S, Fujita T, Takahashi T, Wada Y, Fuke Y, Satomura A, Matsumoto K: TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. J Nephrol 21: 53-63, 2008
32. Kanemoto K, Usui J, Nitta K, Horita S, Harada A, Koyama A, Aten J, Nagata M: In situ expression of connective tissue growth factor in human crescentic glomerulonephritis. Virchows Arch 444: 257-263, 2004
33. Wang SN, LaPage J, Hirschberg R: Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 57: 1002-1014, 2000
34. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J Am Soc Nephrol 17: 2484-2494, 2006
35. Shi Y, Tu Z, Wang W, Li Q, Ye F, Wang J, Qiu J, Zhang L, Bu H, Li Y: Homologous peptide of connective tissue growth factor ameliorates epithelial to mesenchymal transition of tubular epithelial cells. Cytokine 36: 35-44, 2006
36. Gumz ML, Popp MP, Wingo CS, Cain BD: Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line. Am J Physiol Renal Physiol 285: F664-673, 2003
37. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO, Goldschmeding R: Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 27: 1164-1170, 2004
38. Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M, Luscher TF: Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 95: 831-839, 1997
39. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51: 2709-2718, 2002
40. Sanders PW: Effect of salt intake on progression of chronic kidney disease. Curr Opin Nephrol Hypertens 15: 54-60, 2006
41. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L: Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 362: 590-599, 2010
42. Ernst ME, Moser M: Use of diuretics in patients with hypertension. N Engl J Med 361: 2153-2164, 2009
43. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
44. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
45. Adler SG, Schwartz S, Williams ME, Rauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, Sewell KL: Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5: 1420-1428, 2010
46. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R: Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21: 3355-3368, 2007